[Guillain-Barre syndrome and the mass vaccination against A/H1N1. No increase of the risk has been reported so far].
Press
Rayomand
R
Neurologiska Kliniken, Karolinska Universitetssjukhuset, Huddinge. rayomand.press@karolinska.se
Andersen
Oluf
O
D000277:Adjuvants, Pharmaceutic / Q000009:adverse effects; D014943:Global Health; D020275:Guillain-Barre Syndrome / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology*; D049673:History, 20th Century; D006801:Humans; D015994:Incidence; D053118:Influenza A Virus, H1N1 Subtype; D007252:Influenza Vaccines / Q000009:adverse effects* / Q000266:history; D007251:Influenza, Human / Q000517:prevention & control*; D032541:Mass Vaccination / Q000009:adverse effects / Q000266:history; D012307:Risk Factors; D014481:United States / Q000453:epidemiology
D000277:Adjuvants, Pharmaceutic; D007252:Influenza Vaccines